SAGE

Sage Therapeutics, Inc. (SAGE) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Financial Strength

Very strong liquidity with a current ratio of 9.16x and cash ratio of 1.51x.

Balance sheet leverage remains minimal, with debt-to-equity at 0.03x and debt-to-assets at 0.03x.

Net current asset value is positive at $354.9M, supporting downside protection.

Profitability

Gross margin is extremely high at 98.7%, indicating strong product-level economics.

However, operating margin is deeply negative at -265.6% and net margin is -244.7%.

Returns remain negative across ROA (-26.5%), ROE (-28.7%), and ROIC (-31.8%).

Valuation

The company trades at a price-to-book ratio of 1.47x, which is not demanding relative to its cash-rich balance sheet.

Enterprise value to sales is 10.69x, reflecting a premium valuation despite losses.

Negative earnings and free cash flow make traditional earnings-based valuation metrics less meaningful.

Growth Outlook

Revenue per share is modest at 0.73, suggesting the business is still in an early scaling phase.

High gross margin provides room for operating leverage if spending moderates.

No recent news was provided to indicate a near-term catalyst or demand inflection.

Risks

Persistent operating losses and negative free cash flow remain the main financial risk.

The company’s valuation is still sensitive to execution on pipeline, commercialization, and cost discipline.

No recent news was provided, so there is no new event-driven risk to incorporate this month.

Opportunities

A very strong cash position and low leverage give management flexibility to fund development.

High gross margin suggests meaningful operating leverage if revenue scales.

Positive net current asset value provides a cushion while the company works toward profitability.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Sage Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →